MEHMET SERDAR YILDIRIM*, MEHMET SINAN DAL**, ABDULLAH KARAKUŞ**, FERHAT OTO*, MÜCAHIT GÖRÜK*, MEHMET RECAI
AKDOĞAN*, NECIB NAS*, ORHAN AYYILDIZ**
*Dicle University, Faculty of Medicine, Department of Internal Medicine, Diyarbakir, Turkey - **Dicle University, Faculty of Medicine, Department of Hematology, Diyarbakir, Turkey
Background: Thrombosis is triggered by a shift in the balance of procoagulant and anticoagulant factors due to acquired or inherited causes. Factor XIII plays an important role in the stabilization of the linkage between fibrins. Three different genetic structu- re of Valine34Leucine polymorphism in FXIIIA have been described. Valine/Valine structure has been identified as the homozygous normal (wild-type), whereas Valine/Leucine and Leucine/Leucine structures have been identified as heterozygous and homozygous mutants respectively. Genetic polymorphisms in FXIII-A subunit vary substantially from society to society. The primary objective of this study was to determine the relationship between factor XIII polymorphisms and arterial/venous thromboembolism in the southeast of Turkey.
Methods: A total of 127 patients with arterial and venous thrombosis were included as the study group and 102 healthy subjects with no thromboembolic disorders were included as the control group. Val34Leu polymorphism in FXIII was investigated in both grou- ps using PCR (Polymerase chain reaction).
Results: The prevalence of the polymorphism in the study and control groups were compared with chi-square test, no statistical- ly significant differences were found (the prevalence in the study and control group are 68.5% and 66.7% for V/V allele, 29.2% and 29.4% for V/L allele, and 2.4% and 3.9% in L/L allele respectively, with p = 0.787). When deep vein thrombosis (DVT) diagnosed female patients group (n = 8) was compared to the healthy female control group, V/L allele was significantly lower, whereas L/L allele was significantly higher (p = <0.01).
Conclusions: This study indicates that there is no evidence for association between factor XIII-A Val34Leu polymorphism and arterial/venous thromboembolism. The significant result we found for the DVT patients should be strengthened by further studies with greater number of cases. In future, further studies are needed with more specific groups and with greater numbers of patients.
Factor XIII, polymorphism, thrombophilia, venous-arterial thrombosis.